Pfizer (PFE) Ticks Higher; Prevenar 13 Met Primary Objective
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Join SI Premium – FREE
Pfizer (NYSE: PFE) shares are ticking higher following new top-line data from its Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.
Data shows Prevenar 13 met the primary objective for all 13 stereotypes and Pfizer will support further regulatory submissions.
Shares are up about 0.2 percent ahead of the bell.
Data shows Prevenar 13 met the primary objective for all 13 stereotypes and Pfizer will support further regulatory submissions.
Shares are up about 0.2 percent ahead of the bell.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA extends Capricor's deramiocel review deadline to November 2026
- Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S.
- American EcoFuels plans up to 584 new patent filings for fuel tech
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
